Ovapuldencel-T

Drug Profile

Ovapuldencel-T

Alternative Names: Ovarian cancer stem cell therapy - NeoStem Oncology

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hoag Memorial Hospital Presbyterian
  • Developer NeoStem Oncology
  • Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies; Stem cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Ovarian cancer

Most Recent Events

  • 23 Oct 2017 Aivita Biomedical plans a phase II trial for Ovarian, Fallopian tube or Peritoneal cancer (Late stage disease, Metastatic disease) in USA, in November 2017 (NCT02033616)
  • 25 Apr 2016 NeoStem withdraws a phase II trial for Ovarian, Fallopian tube or Peritoneal cancer (Late stage disease, Metastatic disease) in USA priro to enrolment (NCT02033616)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top